Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist
You'll hear more buzz about starting an aldosterone antagonist (spironolactone, eplerenone) in eligible post-MI patients.
This isn't new information. We know adding an aldosterone antagonist to post-MI patients with "systolic" heart failure...or HFrEF...reduces mortality. But less than 20% of patients are started on one.
Help close the gap.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals